Antiparkinsonian Action of a Opioid Agonist in Rodent and Primate Models of Parkinson's Disease

By Hille C.J.   Fox S.H.   Maneuf Y.P.   Crossman A.R.   Brotchie J.M.  

Experimental Neurology, Vol. 172, Iss. 1, 2001-11 ,pp. : 189-198

Elsevier

Access to resources Recommend Favorite

The Antioxidant Ebselen Prevents Neurotoxicity and Clinical Symptoms in a Primate Model of Parkinson's Disease

By Moussaoui S.   Obinu M.-C.   Daniel N.   Reibaud M.   Blanchard V.   Imperato A.  

Experimental Neurology, Vol. 166, Iss. 2, 2000-12 ,pp. : 235-245

Elsevier

Access to resources Recommend Favorite

Animal models of Parkinson’s disease progression

By Meredith Gloria   Sonsalla Patricia   Chesselet Marie-Francoise  

Acta Neuropathologica, Vol. 115, Iss. 4, 2008-04 ,pp. : 385-398

Springer Publishing Company

Access to resources Recommend Favorite

- and -Opioid Receptor Antagonists Reduce Levodopa-Induced Dyskinesia in the MPTP-Lesioned Primate Model of Parkinson's Disease

By Henry B.   Fox S.H.   Crossman A.R.   Brotchie J.M.  

Experimental Neurology, Vol. 171, Iss. 1, 2001-09 ,pp. : 139-146

Elsevier

Access to resources Recommend Favorite

Impairment of context-adapted movement selection in a primate model of presymptomatic Parkinson’s disease

By Pessiglione M.   Guehl D.   Agid Y.   Hirsch E.C.   Féger J.   Tremblay L.  

Brain, Vol. 126, Iss. 6, 2003-06 ,pp. : 1392-1408

Oxford University Press

Access to resources Recommend Favorite